ClinicalTrials.gg
CompletedNCT01561898Updated Sep 28, 2012Results posted

A Long-Term Study of JNS007ER in Patients With Schizophrenia

A Phase 3 interventional study of Paliperidone extended-release (JNS007ER) in Schizophrenia, sponsored by Janssen Pharmaceutical K.K.. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-09-28.

Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
228
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
47th of 115
228 · median 178
Started
2006
with 4 others
Phase 3
41 of 115
none open now
Registered
74th of 115
by date
Lead sponsor
7 of 115
Janssen Pharmaceutical K.K.

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 47th largest by enrollment, is one of 5 that started in 2006, is one of 41 in phase 3, and was the 74th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety of JNS007ER 3-12 mg once daily in patients with schizophrenia over a long term period.

Read the detailed description

This is a 48-week, multicenter, open-label (all people know the identity of the intervention), non-controlled, arbitrary-dose study. The patients included in this study are those who participated in the preceding double-blind (neither physician nor patient knows the treatment that the patient receives) comparative trial (study JNS007ER-JPN-S31) of JNS007ER and completed the study, or those who remained in the study up to the evaluation at 2 weeks and discontinued the study after that for insufficient treatment efficacy. The study will assess the safety of JNS007ER in the clinical recommended dose range in a long term treatment. The dosage will be started at 6 mg/day, and it can be increased or decreased 3 mg at a time depending on the patient's symptom within the range of 3 mg/day to 12 mg/day. For dose adjustments, the investigator will evaluate the psychiatric symptoms before defining the dose change.

Detailed Description: Extended description of the protocol, including more technical information (as compared to the Brief Summary) if desired. Do not include the entire protocol; do not duplicate information recorded in other data elements, such as eligibility criteria or outcome measures.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • JNS007ER
  • Paliperidone extended-release
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with schizophrenia
  • Patients who have given their own consent in writing to participate in the study
  • Patients untreated with antipsychotics within 28 days before the screening test
  • Patients who have completed Study JNS007ER-JPN-S31, or those who continued the study at least up to the evaluation at 2 weeks and subsequently discontinued the study due to insufficient efficacy
  • Patients participating in Study JNS007ER-JPN-S31 and whose ratio of treatment to the evaluation at 2 weeks is ≥75%

Exclusion criteria

Exclusion Criteria:

  • Patients diagnosed with a mental disease other than schizophrenia
  • A total PANSS score > 120 at baseline
  • Substance-related disorders
  • Parkinson's disease complications
  • Current or a past history of convulsive disease such as epilepsy
  • Current or a past history of cerebrovascular accident
  • Diabetes mellitus
  • Significant hepatic or renal impairment
  • Significant cardiovascular disorders
  • Abnormal results of hematological examination, blood chemistry test and urinalysis at screening
  • Pregnant women, breast-feeding mothers, and patients who wish pregnancy during the study period or those whose pregnancy test at screening was positive
  • to risperidone products
  • Patients who discontinued Study JNS007ER-JPN-S31 due to an adverse event not related to the underlying disease
  • Patients judged inadequate by the investigator to participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
228 participants (actual)

Study arms

  • Experimental
    Paliperidone extended-release (JNS007ER)

    Drug: Paliperidone extended-release (JNS007ER)

Interventions

  • Type= range, unit= mg, number= 3-12, form= tablet, route= oral use. JNS007ER within the range of 3, 6, 9 and 12 mg will be orally administered once daily for 48 weeks.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    The incidence of adverse events was measured by the percentage of patients who presented one or more adverse events.

    Time frame: 48 weeks

Secondary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS)

    PANSS is a medical scale that assesses various symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill).

    Time frame: Baseline, Week 48

  2. Change From Baseline in Clinical Global Impression - Severity (CGI-S)

    The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a patient. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill patients".

    Time frame: Baseline, Week 48

07

Results

Posted Sep 10, 2012

Participant flow

This study comprises patients who have participated in previous study JNS007ER-JPN-S31 (NCT00396565) and new patients. New patients were classified as group NO/PAL. Patients entering from study JNS007ER-JPN-S31 were classified according to their origin groups: placebo group (PLA/PAL), paliperidone group (PAL/PAL), and olanzapine group (OLZ/PAL).

Participant flow — Overall Study
MilestoneNO/PAL GroupPLA/PAL GroupPAL/PAL GroupOLZ/PAL
Started7929732
Completed5515312
Not completed2414420
Withdrew: Withdrawal by subject08125
Withdrew: Lack of efficacy08105
Withdrew: Worsening of complications0100
Withdrew: Lost to follow-up0010
Withdrew: Adverse event119149
Withdrew: Physician decision1571

Outcome measures

SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS)

PANSS is a medical scale that assesses various symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill).

Time frame:
Baseline, Week 48
Reported as:
Mean · scores on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS)
scores on a scaleNO/PALPLA/PAL GroupPAL/PAL GroupOLZ/PAL
Change From Baseline in Positive and Negative Syndrome Scale (PANSS)-13.4 ± 31.93-11.1 ± 20.84-17.2 ± 22.152.8 ± 20.67
SecondaryChange From Baseline in Clinical Global Impression - Severity (CGI-S)

The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a patient. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill patients".

Time frame:
Baseline, Week 48
Reported as:
Mean · scores on a scale
Change From Baseline in Clinical Global Impression - Severity (CGI-S)
scores on a scaleNO/PALPLA/PAL GroupPAL/PAL GroupOLZ/PAL
Change From Baseline in Clinical Global Impression - Severity (CGI-S)-0.6 ± 1.27-0.6 ± 1.20-0.7 ± 1.240.1 ± 1.01
PrimaryIncidence of Adverse Events

The incidence of adverse events was measured by the percentage of patients who presented one or more adverse events.

Time frame:
48 weeks
Reported as:
Number · percentage of patients
Incidence of Adverse Events
percentage of patientsEntire Group
Incidence of Adverse Events97.4

Adverse events

Collected over 48 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Entire Group—10/228 (4.4%)222/228 (97.4%)
Most frequent serious events
Most frequent serious events
EventEntire Group
SchizophreniaPsychiatric disorders3/228
PneumoniaInfections and infestations2/228
InsomniaPsychiatric disorders1/228
AkathisiaNervous system disorders1/228
Pulmonary aspirationRespiratory, thoracic and mediastinal disorders1/228
Multiple organ failureGeneral disorders1/228
ECG corrected QT interval prolongedCardiac disorders1/228
OverdoseGeneral disorders1/228
Most frequent other events
Showing 10 of 19
Most frequent other events
EventEntire Group
Blood prolactin increasedInvestigations91/228
NasopharyngitisInfections and infestations77/228
SchizophreniaPsychiatric disorders69/228
Weight increasedGeneral disorders50/228
Extrapyramidal disorderNervous system disorders39/228
ConstipationGastrointestinal disorders32/228
Blood creatine phosphokinase increasedMetabolism and nutrition disorders28/228
Blood triglycerides increasedMetabolism and nutrition disorders23/228
InsomniaPsychiatric disorders23/228
EczemaSkin and subcutaneous tissue disorders20/228

Baseline characteristics

Age Continuous
Age Continuous(years)NO/PAL GroupPLA/PAL GroupPAL/PAL GroupOLZ/PALTotal
Mean35.6 ± 14.846.6 ± 15.542.0 ± 14.146.3 ± 14.044.3 ± 14.9
Sex: Female, Male
Sex: Female, Male(Participants)NO/PAL GroupPLA/PAL GroupPAL/PAL GroupOLZ/PALTotal
Female3444620113
Male4485112115
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2012
First posted
Mar 23, 2012
Start
Jun 2006
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Sep 10, 2012
Last update
Sep 28, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01561898
First posted
Mar 23, 2012
Start date
Jun 2006
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Sep 10, 2012
Last update
Sep 28, 2012

Study contacts

Janssen Pharmaceutical K.K., Japan Clinical Trial
study director · Janssen Pharmaceutical K.K.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion